Rib-X's skin infection drug enters late-stage study

05/17/2013 | Pharmaceutical Business Review Online

Rib-X Pharmaceuticals initiated a late-stage trial to assess the efficacy of a Captisol-enabled IV formulation of delafloxacin in patients with acute bacterial skin and skin structure infections. The trial triggered the payment of a $500,000 milestone fee to partner Ligand Pharmaceuticals.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC